Gilead’s Genvoya approved in China for the treatment of HIV-1 infection

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

China National Drug Administration approves Gilead Sciences' (NASDAQ:GILD) Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection.

Genvoya is the first TAF-based single tablet regimen for the treatment of HIV to be approved in China. In the U.S., Genvoya has a boxed warning in its label regarding the risks of hepatitis B post treatment.

Shares are up a fraction premarket.

Subscribe for full text news in your inbox